Deficient Sarcolemma Repair in ALS: A Novel Mechanism with Therapeutic Potential

Ang Li,Jianxun Yi,Xuejun Li,Li Dong,Jianjie Ma,Jingsong Zhou,Lyle W. Ostrow

DOI: https://doi.org/10.3390/cells11203263

IF: 6

2022-10-18

Cells

Abstract:The plasma membrane (sarcolemma) of skeletal muscle myofibers is susceptible to injury caused by physical and chemical stresses during normal daily movement and/or under disease conditions. These acute plasma membrane disruptions are normally compensated by an intrinsic membrane resealing process involving interactions of multiple intracellular proteins including dysferlin, annexin, caveolin, and Mitsugumin 53 (MG53)/TRIM72. There is new evidence for compromised muscle sarcolemma repair mechanisms in Amyotrophic Lateral Sclerosis (ALS). Mitochondrial dysfunction in proximity to neuromuscular junctions (NMJs) increases oxidative stress, triggering MG53 aggregation and loss of its function. Compromised membrane repair further worsens sarcolemma fragility and amplifies oxidative stress in a vicious cycle. This article is to review existing literature supporting the concept that ALS is a disease of oxidative-stress induced disruption of muscle membrane repair that compromise the integrity of the NMJs and hence augmenting muscle membrane repair mechanisms could represent a viable therapeutic strategy for ALS.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore new mechanisms of impaired muscle cell membrane repair mechanisms in Amyotrophic Lateral Sclerosis (ALS) and evaluate its potential as a treatment strategy for ALS. Specifically, the paper focuses on the phenomenon of decreased muscle cell membrane repair ability in ALS patients, especially the dysfunction of the protein MG53 related to sarcolemma repair. The study found that during the ALS process, mitochondrial dysfunction leads to an increase in the production of Reactive Oxygen Species (ROS), which triggers abnormal aggregation of MG53 and thus loses its function. This decline in membrane repair ability further exacerbates the fragility of the sarcolemma, forming a vicious cycle in which increased sarcolemma damage leads to more oxidative stress, which further damages the sarcolemma.

The paper also explored enhancing the membrane repair mechanism in ALS mouse models by exogenous administration of recombinant human MG53 (rhMG53). The results showed that rhMG53 can reduce sarcolemma leakage, protect the diaphragm neuromuscular junctions (NMJs) and the cell bodies of anterior horn motor neurons in the spinal cord, prolong the lifespan of ALS mice and slow down weight loss. These findings suggest that MG53 - mediated enhancement of membrane repair may become a new treatment strategy for ALS.